DSIP, short for delta sleep-inducing peptide, is a nine-amino-acid neuropeptide that was first isolated from the blood of rabbits in an experimentally induced sleep state. It was named for its apparent ability to promote delta, or slow-wave, EEG activity in the animals used in early experiments. Decades later, DSIP remains an intriguing but unresolved research compound, and this guide summarizes what is known about its structure, proposed mechanisms, lab handling and quality control.
What is DSIP?
DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE). It was originally identified in cerebral venous blood collected from rabbits during sleep induced by electrical stimulation of the brain. When the isolated material was given to other animals, researchers reported increases in slow-wave EEG activity, which led to its name. The synthetic peptide is sometimes referred to by the name emideltide.
Since its discovery, DSIP or DSIP-like immunoreactivity has been reported in the brain, the pituitary and several peripheral tissues, as well as in plasma. However, no gene coding specifically for DSIP has been clearly identified, and no dedicated receptor has been confirmed. This has made DSIP an unusual case: a peptide with a long research history whose biological origin and target remain open questions.
DSIP is a research compound. It is not an approved medicine in the United States, and PRIME supplies it for laboratory research use only.
How DSIP works: mechanism studied in research
The honest answer is that the mechanism of DSIP is not well established. Findings across studies have been inconsistent, and several hypotheses have been proposed rather than confirmed.
Sleep and EEG activity
The original interest in DSIP came from observations of increased slow-wave EEG activity in animal models. Later studies produced mixed results, with some reporting effects on sleep architecture and others finding little or no effect. Differences in species, route of administration, timing and measurement methods are often cited as reasons for the variability.
Neurotransmitter systems
Researchers have explored whether DSIP modulates neurotransmitter systems, including GABAergic, glutamatergic and serotonergic signaling. Some work has examined interactions with NMDA receptor function. These remain areas of investigation rather than settled mechanisms.
Neuroendocrine and stress signaling
DSIP has been studied for possible interactions with the hypothalamic-pituitary axis, including stress hormone release and other pituitary hormones. Animal studies have examined how DSIP relates to stress responses, which has led some researchers to describe it as a modulator of stress adaptation rather than a direct sleep-inducing agent.
Areas of research
DSIP has been investigated mostly in animal models, with a smaller number of early exploratory human studies. Research themes include:
- Sleep architecture and slow-wave EEG activity
- Circadian rhythm regulation
- Stress response and adaptation in animal models
- Neuroendocrine signaling, including pituitary hormone release
- Withdrawal behavior in animal models of substance dependence
- Pain perception and nociception models
- Oxidative stress and cellular protection in experimental systems
Because results have been inconsistent, many reviews treat DSIP as a compound whose physiological role is still unclear. That uncertainty is also part of its appeal to researchers: open questions about its origin, its target and its relationship to sleep regulation leave room for well-controlled studies using modern analytical and imaging methods that were not available when the peptide was first described.
Practical challenges in DSIP research
Researchers working with DSIP face several practical challenges. The peptide is short and unprotected at both ends, and it has been reported to be broken down relatively quickly by peptidases in biological fluids, which complicates interpretation of results from experiments that rely on systemic delivery. Measuring endogenous DSIP has also been difficult, since detection has often relied on antibody-based methods that may recognize related molecules. For these reasons, careful controls, confirmed starting material and clearly documented handling conditions are especially important in DSIP studies. Some groups have also explored modified analogs designed to improve stability, which remain part of the broader research picture around this peptide.
Key facts table
| Property | DSIP |
|---|---|
| Class | Neuropeptide (nonapeptide) |
| Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE) |
| Other names | Delta sleep-inducing peptide, emideltide |
| Origin | First isolated from rabbit cerebral venous blood during induced sleep |
| Known receptor | None confirmed |
| Form supplied | Lyophilized powder in a sealed vial |
| Research status | Research compound; not an approved medicine in the US |
| Storage | Cold, dry and protected from light; refrigerate after reconstitution |
Handling and storage in the lab
DSIP is supplied as a lyophilized powder. Its tryptophan residue can be sensitive to light and oxidation, so careful storage is worthwhile.
- Before reconstitution: keep vials sealed, cold, dry and away from light. For longer storage, freezer conditions are commonly used.
- Reconstitution: labs typically use bacteriostatic water or another sterile diluent suited to the protocol. Add the diluent slowly and swirl gently rather than shaking.
- After reconstitution: keep the solution refrigerated in a light-protected container and label it with the date, lot number and concentration.
- Stability: short peptides can degrade in solution over time. Preparing single-use aliquots helps avoid repeated freeze-thaw cycles.
These are general laboratory handling notes only and are not guidance for personal use of any kind.
Quality and lab results
With a peptide whose reported effects vary between studies, starting material of confirmed identity and purity is essential for interpretable results. Every PRIME batch is independently tested, and the certificate of analysis for each lot is available on the lab results page. Match your vial's lot number to its report and keep it with your records. Research material is available on the DSIP product page.
Related research
DSIP is often discussed alongside other neuroactive peptides studied in stress, sleep and aging research. See the Selank research guide for a peptide studied in anxiety and stress models, the Semax research guide for a related neuropeptide line of research, and the Epithalon research guide for a peptide investigated in circadian and aging research.
FAQ
What does DSIP stand for?
DSIP stands for delta sleep-inducing peptide. It was named after early observations of increased slow-wave, or delta, EEG activity in animals given the isolated peptide.
What is the amino acid sequence of DSIP?
DSIP is a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, often written as WAGGDASGE.
Does DSIP have a known receptor?
No dedicated receptor for DSIP has been confirmed. Researchers have proposed interactions with several neurotransmitter and neuroendocrine systems, but its mechanism remains unresolved.
Is DSIP FDA approved?
No. DSIP is a research compound and is not an approved medicine in the United States. PRIME supplies it for laboratory research use only.
Why are DSIP research results inconsistent?
Studies have used different species, delivery methods, timing and measurement techniques, and the peptide can be unstable in biological fluids. These factors are commonly cited to explain mixed findings.
For laboratory research use only. Not for human consumption. Not a drug, food or cosmetic.